J

ust as the biotech world penciled in Kite Pharma as the winner of the race to launch the first CAR-T cancer therapy, Novartis crept in from behind and took the lead. But beyond fueling a day-to-day debate among insiders, is coming in first in CAR-T really all that important?

With Wednesday’s announcement, Novartis is on track to win a pioneering FDA approval in about six months. Kite, which has promised to file its lead CAR-T any day now, will have to wait on the agency to accept its application and decide whether to give the company the fast-track review it granted Novartis. Advantage: Swiss pharma behemoth.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.